Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease
Journal of Gastroenterology · 2026-07 · 61 (7) · 863-879
DOI: 10.1007/s00535-026-02388-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology, online erschienen am 19.03.2026. Verfasst von Haruka Okada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Jap…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Fusion Oriented REsearch for disruptive Science and Technology.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is frequently accompanied by colitis with clinicopathologic features that differ from conventional inflammatory bowel disease (IBD). Accumulating evidence indicates that PSC-associated IBD (PSC-IBD) often presents as extensive colitis with a right-sided predominant distribution and characteristic endoscopic features, such as rectal sparing and backwash ileitis. Beyond endoscopic appearance, PSC-IBD also appears to have distinct biological underpinnings, including shared genetic susceptibility, dysregulated bile acid signaling, altered gut microbial communities, and immune crosstalk along the gut–liver axis. These mechanisms may contribute not only to intestinal inflammation but also to PSC-related clinical outcomes. From a long-term perspective, patients with PSC and colitis are consistently classified as a high-risk group for colorectal neoplasia, warranting early and intensive colonoscopic surveillance. In parallel, surveillance for hepatobiliary malignancies remains central in PSC care, although risk stratification continues to evolve. Therapeutic management generally follows established IBD algorithms, yet the extent to which colitis-directed therapies modify PSC outcomes remains uncertain, with heterogeneous findings across cohorts and endpoints. In this review, we summarize current knowledge on the clinical phenotype, mechanistic framework, and outcome-driven management of PSC-IBD, and highlight future directions toward precision surveillance and mechanism-based interventions targeting bile acid–microbiota–immune interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. sugimoto-kei@umin.ac.jp.
- Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. nobuhiro.z2@keio.jp.
ORCID-Profile: Nobuhiro Nakamoto
Förderung
- Japan Society for the Promotion of Science
- Fusion Oriented REsearch for disruptive Science and Technology
Zitieren
APA
Okada, H., Sugimoto, S., Kayashima, A., Mikami, Y., Kanai, T., Nakamoto, N., & Keio PSC–IBD Collaborators (2026). Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease. Journal of Gastroenterology, 61(7), 863-879. https://doi.org/10.1007/s00535-026-02388-3
Vancouver
Okada H, Sugimoto S, Kayashima A, Mikami Y, Kanai T, Nakamoto N, et al. Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease. Journal of Gastroenterology. 2026;61(7):863-879. doi:10.1007/s00535-026-02388-3
BibTeX
@article{Okada2026,
author = {Okada, Haruka and Sugimoto, Shinya and Kayashima, Atsuto and Mikami, Yohei and Kanai, Takanori and Nakamoto, Nobuhiro and Keio PSC–IBD Collaborators, Keio PSC–IBD Collaborators},
title = {Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {7},
pages = {863--879},
doi = {10.1007/s00535-026-02388-3}
}
EUVIMED